Extended survival in a case of metastatic choroidal melanoma with immunotherapy
Anti-Cancer Drugs, cilt.35, sa.10, ss.974-978, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 35 Sayı: 10
- Basım Tarihi: 2024
- Doi Numarası: 10.1097/cad.0000000000001650
- Dergi Adı: Anti-Cancer Drugs
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.974-978
- Anahtar Kelimeler: choroidal melanoma, immunotherapy, ipilimumab, liver metastasis, nivolumab, survival, uveal melanoma
- Ankara Üniversitesi Adresli: Evet
Özet
Uveal melanoma is the most common intraocular malignancy in adults. Despite advances in local treatments, approximately 50% of all cases eventually die from metastatic disease. In cases with metastasis, 2-and 5-year survival rates are approximately 10% and <1%, respectively. Advances in molecular biology have led to the identification of a number of promising drugs including immune checkpoint inhibitors (ICIs). Ipilimumab and nivolumab are ICIs targeting the cytotoxic T-lymphocyte-Associated antigen-4 and the programmed-cell death protein-1, respectively. Herein, we present a case of choroidal melanoma having liver metastasis treated with nivolumab and ipilimumab and transarterial radioembolization, achieving a 3-year survival.